Autonomix Releases CEO Segment Highlighting 13 Abstracts, Top CRT Innovation Award
AMIX•Autonomix released a CEO Corner segment highlighting 13 abstract acceptances—nine podium and four poster presentations at TCT, CRT, SIR and ASCO—and a top CRT Cardiovascular Innovation Award. He says the platform’s real-time nerve-sensing and transvascular denervation could transform pancreatic cancer pain treatment and support U.S. trials, physician adoption and reimbursement.
1. CEO Corner Segment Release
Autonomix released its latest CEO Corner segment featuring President and CEO Brad Hauser, outlining recent milestones and strategic plans. The segment is available on the company’s website and social media channels to inform investors and stakeholders of ongoing developments.
2. Scientific Recognition and Awards
Since last fall, Autonomix secured 13 peer-reviewed abstracts—nine podium and four poster presentations—at Transcatheter Cardiovascular Therapeutics (TCT), Cardiovascular Research Technologies (CRT), Society of Interventional Radiology (SIR) and the American Society of Clinical Oncology Annual Meeting (ASCO). The company also received the top CRT Cardiovascular Innovation Award, underscoring the novelty and potential impact of its nerve-sensing and transvascular denervation technology.
3. Clinical Impact and Strategic Outlook
Brad Hauser emphasized the platform’s capability to transform pancreatic cancer pain treatment through real-time nerve sensing and targeted therapy. He detailed plans to leverage these scientific recognitions to advance U.S. clinical trials, forge strategic partnerships and pursue reimbursement pathways to drive physician adoption and market access.
